某院门诊糖尿病患者降糖药使用情况分析-现代医学

某院门诊糖尿病患者降糖药使用情况分析

单位：1. 泰州市第三人民医院药剂科, 江苏泰州 225300;
2. 泰州市人民医院药学部, 江苏泰州 225300

分类号：R977.15

出版年·卷·期（页码）：2025·53·第三期（425-430）

摘要：

目的：分析泰州市第三人民医院门诊糖尿病患者降糖药的使用情况，为临床合理用药提供依据。方法：纳入泰州市第三人民医院2022年9月至2023年11月门诊糖尿病患者4 023例，对患者性别、年龄、用药情况、用药方案等进行描述性统计。结果：老年(≥60岁)患者数量最多，占65.87%；而儿童(0~14岁)患者数量最少，占0.27%。男女性别比为1.19∶1。使用最多的降糖药物为达格列净，其次为二甲双胍缓释片和门冬胰岛素注射液。男性患者用药频次整体上大于女性患者。不同年龄患者中，儿童患者用药频次最低，而老年患者用药频次最高。对于不同的用药方案，两药联用的患者最多，单药治疗和两药联用方案在男性和女性患者分布上差异无统计学意义(P＞0.05)，但在患者的年龄分布上差异有统计学意义(P<0.05)。结论：糖尿病的发病率在男性中略高于女性，且随着年龄的增长，糖尿病患病的风险会逐渐增加。目前临床上降糖药使用最为广泛的是达格列净。患者应当通过调整生活习惯、加强运动等综合措施对糖尿病进行预防和控制。

Objective: To analyze the use of hypoglycemic drugs in outpatients with diabetes in Taizhou Third People's Hospital, to provide basis for clinical rational drug use. Methods: 4 023 outpatients with diabetes in Taizhou Third People's Hospital from September 2022 to November 2023 were collected, and their gender, age, medication situation and medication plan were analyzed. Results: The number of elderly(≥60 aged) patients was the highest, accounting for 65.87%; while the number of pediatric(≤14 years old) patients was the lowest, accounting for 0.27%. The male/female patient ratio was 1.19. The most commonly used hypoglycemic drug is dapagliflozin, followed by metformin sustained-release tablets and insulin aspartate injection. The frequency of medication use among male patients is generally higher than that among female patients. Among patients of different ages, pediatric patients have the lowest medication frequency, while elderly patients have the highest medication frequency. For different medication regimens, patients using two drugs in combination were the most. There was no statistically significant difference in the use of single drug treatment and two-drug combination regimens between male and female patients(P>0.05), but there was a statistically significant difference in the age distribution of patients(P<0.05). Conclusion: The incidence of diabetes is slightly higher in males than in females, with a progressive age-dependent increase in disease risk. Dapagliflozin is currently the most widely used hypoglycemic drug in clinical practice. Patients should prevent and control diabetes through comprehensive measures such as adjusting lifestyle and strengthening exercise.

参考文献：

[1] 黄焱.降糖药物不良反应及注意事项分析[J].中国社区医师,2024,40(11):3-5.
[2] 向玉芳,孙辉,陈月,等.2型糖尿病降糖药不良反应及联合用药情况分析[J].中国药物警戒,2022,19(3):313-316.
[3] 张明丽.双胍类降糖药物对2型糖尿病治疗的效果及不良反应分析[J].自我保健,2022,26(19):283-285.
[4] 苗丰,孙媛,罗建梅.临床口服降糖药不良反应发生情况分析[J].海南医学,2022,33(18):2407-2409.
[5] 于恒彩,葛兰兰,聂瑞芳,等.某三级甲等医院抽查的100例 2 型糖尿病住院患者的抗糖尿病药使用合理性分析[J].中国医院用药评价与分析,2022,22(10):1259-1263.
[6] 薛泽臻，刘碧婷，李莉.糖尿病患者降糖药物的用药情况及合理用药指导[J].黑龙江医学,2021,45(11):1181-1182,1185.
[7] 中国国家统计局.中国统计年鉴[M].北京：中国统计出版社，2020.
[8] 闫阔，张楠，陆红柳，等.瑞格列奈与氯吡格雷相互作用致低血糖的风险评估[J].中国药事,2021,5(7):768-775.
[9] 骆超锋,梁叠锋,关国宏.瑞格列奈联合胰岛素治疗2型糖尿病临床疗效及对患者血糖水平的影响[J].广州医药,2021,52(4):65-67,91.
[10] 裴智勇,刘满姣,陈禹保.不同人群2型糖尿病的易感基因分析研究进展[J].国际检验医学杂志，2017,38(24):3434-3439.
[11] LIU J,WANG L,QIAN Y,et al.Analysis of the interaction effect of 48 SNPs and obesity on type 2 diabetes in Chinese Hans[J].BMJ Open Diabetes Res Care,2020,8(2):e001638.
[12] 曹慧颖,冯磊,唐灵通,等.遗传风险评分在预测2型糖尿病中的进展[J].中华全科医学,2023,21(8):1383-1387.
[13] 蔡慧雅.2018年7月～12月我院门诊口服降糖药用药分析[J].海峡药学,2020,32(2):181-183.
[14] 薛泽臻,刘碧婷,李莉.糖尿病患者降糖药物的用药情况及合理用药指导[J].黑龙江医学,2021,45(11):1181-1182,1185.
[15] 曹顺东,刘丽玲.临床合理用药指导对2型糖尿病患者用药依从性的作用分析[J].糖尿病新世界,2022,25(2):111-114.
[16] 杨晨.临床合理用药指导对2型糖尿病患者用药依从性的影响[J].中国实用医药,2022,17(9):173-175.
[17] 庄俊鹏,林小燕,蔡晓艳.药物指导干预对糖尿病患者合理用药和生化指标的影响分析[J].海峡药学,2021,33(5):180-181.
[18] PAN X R,LI G W,HU Y H,et al.Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolernce-the DaQing IGT and diabetes study[J].Diabetes Care,1997,20(4):537-544.
[19] LI G,ZHANG P,WANG J,et al.The long-term effect of life,style interventions to prevent diabetes in the China DaQing diabetes prevention study:a 20-year follow-up study[J].Lancet,2008,371(9626):1783-1789.
[20] AN Y,ZHANG P,WANG J,et al.Cardiovascular and all-cause mortality over a 23-year period among Chinese with newly diagnosed diabetes in the DaQing IGT and diabetes study[J].Diabetes Care,2015,38(7):1365-1371.
[21] GONG Q,ZHANG P,WANG J,et al.Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance:30-year results of the DaQing diabetes prevention outcome study[J].Lancet Diabetes Endocrinol,2019,7(16):452-461.
[22] 张丹丹,李婷婷.患者参与健康模型在2型糖尿病患者健康管理中的应用[J].湖北科技学院学报(医学版),2024,38(6):535-537.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录